Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 11, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Journal: Therapeutic advances in neurological disorders
Published: July 23, 2020
Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis.
Journal: International journal of MS care
Published: May 16, 2020
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: April 20, 2020
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 26, 2019
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
Journal: Neurology and therapy
Published: July 03, 2019
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: May 15, 2019
Showing 1-7 of 7
Last Updated: 09/26/2026